Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: Results of a phase i dose escalation trial

British Journal of Cancer

Volumn 105, Issue 11, 2011, Pages 1646-1653

  Melichar, B ^a,b   Casado, E ^c   Bridgewater, J ^d   Bennouna, J ^e   Campone, M ^e   Vitek, P ^f   Delord, J P ^g   Cerman, Jr ^a   Salazar, R ^c   Dvorak, J ^a   Sguotti, C ^h   Urban, P ^h   Viraswami Appanna, K ^h   Tan, E ^h   Tabernero, J ^c  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Team 12   (France)

^f CHARLES UNIVERSITY   (Czech Republic)

^g INSTITUT CLAUDIUS REGAUD   (France)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

dose escalation; epothilone B; metastatic colon cancer; microtubule stabiliser; patupilone

Indexed keywords

EPOTHILONE B; LOPERAMIDE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER CONTROL; COLON CANCER; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLATULENCE; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; SIDE EFFECT; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOTHILONES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 82055198578     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.438     Document Type: Article

References (41)

1. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P, Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86: 446-449 (Pubitemid 24081877)
2. Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F (2000) Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr 71: 339S-342S (Pubitemid 30046138)
3. Benson III AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson Jr JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22: 2918-2926 (Pubitemid 41079912)
4. Bjorck S, Bosaeus I, Ek E, Jennische E, Lonnroth I, Johansson E, Lange S (2000) Food induced stimulation of the antisecretory factor can improve symptoms in human inflammatory bowel disease: a study of a concept. Gut 46: 824-829 (Pubitemid 30329078)
5. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubulestabilizing agents with a taxol-like mechanism of action. Cancer Res 55: 2325-2333
6. Chi KN, Beardsley E, Eigl BJ, Venner P, Hotte SJ, Winquist E, Ko YJ, Sridhar SS, Weber D, Saad F (2011) A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Ann Oncol; e-pub ahead of print 16 July 2011; doi: 10.1093/annonc/mdr336
7. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418 (Pubitemid 28510874)
8. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 351: 337-345 (Pubitemid 38944402)
9. Daniele B, Perrone F, Gallo C, Pignata S, De Martino S, De Vivo R, Barletta E, Tambaro R, Abbiati R, D'Agostino L (2001) Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut 48: 28-33 (Pubitemid 32042638)
10. Eng C, Kindler HL, Nattam S, Ansari RH, Kasza K, Wade-Oliver K, Vokes EE (2004) A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 15: 928-932 (Pubitemid 39004349)
11. Forster M, Kaye S, Oza A, Sklenar I, Johri A, Cheung W, Zaknoen S, Gore M (2007) A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin Cancer Res 13: 4178-4184 (Pubitemid 47105981)
12. Fumoleau P, Coudert B, Isambert N, Ferrant E (2007) Novel tubulintargeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 18(Suppl 5): v9-v15
13. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 25: 1539-1544 (Pubitemid 46733080)
14. Gibson GR (1998) Dietary modulation of the human gut microflora using prebiotics. Br J Nutr 80: S209-S212 (Pubitemid 28510689)
15. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30 (Pubitemid 41095110)
16. Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214 (Pubitemid 41079833)
17. Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y, Satoh T (1995) Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Dispos 23: 1022-1027
18. Hurwitz H, Fehrenbacher L, Nowotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342 (Pubitemid 38702844)
19. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR (2009) Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 20: 492-497
20. Jonker D, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048 (Pubitemid 350106711)
21. Juntunen M, Kirjavainen PV, Ouwehand AC, Salminen SJ, Isolauri E (2001) Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol 8: 293-296 (Pubitemid 32217059)
22. Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, Stiff PJ, Vokes E, Wadler S (2000) Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage 19: 118-129 (Pubitemid 30116801)
23. Kowalski RJ, Giannakakou P, Hamel E (1997) Activities of the microtubulestabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 272: 2534-2541 (Pubitemid 27058547)
24. McSheehy P, Becquet M, Boisclair J, Bizot MN (2008) Prednisolone abrogates patupilone (EPO906)-induced diarrhoea in rats without impacting on patupilone PK or efficacy. [abstract] Proceedings of the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics EJC Suppl 6: 451
25. Meta-analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308
26. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487
27. O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM (2008) Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anticancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 62: 1045-1054
28. Poplin E, Moore M, O'Dwyer P, Clarke S, Hill M, Sessa C, Rothermel J, Mull R, Miller J, Rosen L (2003) Safety and efficacy of EPO906 in patients with advanced colorectal cancer: a review of 2 phase II trials. Proc ASCO 22: 1135
29. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069 (Pubitemid 46606353)
30. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412 (Pubitemid 28510873)
31. Rubin EH, Rothermel J, Tesfaye F, Chen T, Hubert M, Ho YY, Hsu CH, Oza AM (2005) Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 23: 9120-9129
32. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kroning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris III HA (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311-2319
33. Sridhar SS, Hotte SJ, Kollmannsberger CK, Mukherjee SD, Capier K, Barclay J, Adams L, Weber D, Chi KN (2010) Preventing patupiloneinduced diarrhea with high-dose corticosteroids. J Clin Oncol 28(Suppl): e13069
34. Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45: 925-937 (Pubitemid 19249331)
35. Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA, Cottrell J, Guemei A, Llorens V, Hehman H, Ismail AS, Flemming D, Gosky DM, Hirota H, Berger SJ, Berger NA, Chen AP, Shapiro JD, Arbuck SG, Wright J, Hamilton JM, Allegra CJ, Grem JL (2000) Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. J Clin Oncol 18: 659-667 (Pubitemid 30078548)
36. Tang PA, Bentzen SM, Chen EX, Siu LL (2007) Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25: 4562-4568 (Pubitemid 350035313)
37. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, Spanik S, Wagnerova M, Hirte HW, Kaye S, Johri AR, Oza AM (2009) Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol 27: 3097-3103
38. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG, Erdkamp FLG, Vos AH, van Groeningen CJ, Sinnige HAM, Richel DJ, Voest EE, Dijskstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JHJM, Dalesio O, Punt CJA (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572
39. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237 (Pubitemid 41095086)
40. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chien CRC, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roj JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schliting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417
41. Wadler S, Benson III AB, Engelking C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E (1998) Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16: 3169-3178 (Pubitemid 28417440)